{"id":2150,"date":"2022-06-09T14:40:59","date_gmt":"2022-06-09T14:40:59","guid":{"rendered":"https:\/\/www.esig.org\/newsletters\/?page_id=2150"},"modified":"2022-06-21T13:35:13","modified_gmt":"2022-06-21T13:35:13","slug":"sector-news-ospa","status":"publish","type":"page","link":"https:\/\/www.esig.org\/newsletters\/2022\/summer\/sector-news-ospa\/","title":{"rendered":"2022 Summer : Sector News \u2013 OSPA"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_color=”RGBA(0,0,0,0)” z_index=”1″ min_height=”100vh” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_row column_structure=”1_2,1_2″ admin_label=”Arrows” module_class=”navArrows” _builder_version=”4.9.4″ _module_preset=”default” background_color=”#412E68″ positioning=”fixed” position_origin_f=”bottom_right” vertical_offset=”25px” horizontal_offset=”25px” z_index=”100″ width=”132px” height=”66px” custom_padding=”0px|10px|0px|10px|true|true” custom_css_main_element=”display: flex;” border_radii=”on|40px|40px|40px|40px” saved_tabs=”all” collapsed=”off”][et_pb_column type=”1_2″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_image src=”https:\/\/www.esig.org\/newsletters\/wp-content\/uploads\/2021\/05\/round.svg” alt=”White Round” title_text=”White Round” url=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjIxMzcifX0=@” admin_label=”Link To Previous Page” _builder_version=”4.9.4″ _dynamic_attributes=”url” _module_preset=”default” positioning=”absolute” vertical_offset=”10px” width=”46px” height=”46px”][\/et_pb_image][et_pb_image src=”https:\/\/www.esig.org\/newsletters\/wp-content\/uploads\/2021\/05\/arrow-left.svg” alt=”Arrow Left” title_text=”Arrow Left” admin_label=”Arrow Left” _builder_version=”4.9.4″ _module_preset=”default” positioning=”absolute” vertical_offset=”10px” horizontal_offset=”10px” width=”23px” height=”46px” custom_css_main_element=”pointer-events: none;”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_image src=”https:\/\/www.esig.org\/newsletters\/wp-content\/uploads\/2021\/05\/round.svg” alt=”White Round” title_text=”White Round” url=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjIxNjUifX0=@” admin_label=”Link To Next Page” _builder_version=”4.9.4″ _dynamic_attributes=”url” _module_preset=”default” positioning=”absolute” position_origin_a=”top_right” vertical_offset=”10px” width=”46px” height=”46px”][\/et_pb_image][et_pb_image src=”https:\/\/www.esig.org\/newsletters\/wp-content\/uploads\/2021\/05\/arrow-right.svg” alt=”Arrow Right” title_text=”Arrow Right” admin_label=”Arrow Right” _builder_version=”4.9.4″ _module_preset=”default” positioning=”absolute” position_origin_a=”top_right” vertical_offset=”10px” horizontal_offset=”10px” width=”23px” height=”46px” custom_css_main_element=”pointer-events: none;”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ use_custom_gutter=”on” gutter_width=”1″ make_equal=”on” custom_padding_last_edited=”on|tablet” admin_label=”Header : Standard” module_class=”reverse” _builder_version=”4.9.4″ _module_preset=”default” background_enable_color=”off” background_enable_image=”off” width=”100%” width_tablet=”” width_phone=”” width_last_edited=”on|phone” module_alignment=”center” min_height=”100vh” overflow-x=”hidden” overflow-y=”hidden” custom_padding=”0px||0px||false|false” custom_padding_tablet=”0px||0px||false|false” custom_padding_phone=”||||false|false” custom_css_main_element=”display: flex;”][et_pb_column type=”1_2″ _builder_version=”4.9.4″ _module_preset=”default” background_color=”RGBA(0,0,0,0)” custom_padding=”|6%||6%|false|true” custom_padding_tablet=”|10%|50px|10%|false|true” custom_padding_phone=”|10%||10%|false|false” custom_padding_last_edited=”off|phone”][et_pb_image src=”https:\/\/www.esig.org\/newsletters\/wp-content\/uploads\/2022\/06\/Logo_ospa.jpg” title_text=”Logo_ospa” _builder_version=”4.9.4″ _module_preset=”default” module_alignment=”center” custom_margin=”80px||||false|false” custom_margin_tablet=”” custom_margin_phone=”” custom_margin_last_edited=”on|tablet”][\/et_pb_image][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” header_2_font=”|700|||||||” header_2_text_align=”left” header_2_text_color=”#412E68″ header_2_line_height=”1.2em” custom_padding=”||16px|||” header_2_font_size_tablet=”24px” header_2_font_size_phone=”22px” header_2_font_size_last_edited=”on|phone”]<\/p>\n

E-series publications<\/h2>\n

[\/et_pb_text][et_pb_text admin_label=”Text” _builder_version=”4.9.4″ _module_preset=”default” text_line_height=”1.9em” module_alignment=”center” custom_padding=”||40px||false|false”]<\/p>\n

The glycol ethers group contributed to a publication by Jeff Kelsey on available literature and data on endocrine disrupting properties of the E-series glycol ethers (EGE). The article called \u201cEthylene oxide derived glycol ethers: A review of the alkyl glycol ethers potential to cause endocrine disruption\u201d was published in March in \u201cRegulatory Toxicology and Pharmacology\u201d. The extensive analysis done shows that there appears to be no significant evidence to support other published claims that EGE disrupt the endocrine system.<\/p>\n

A similar article is being prepared for the P-series glycol ethers.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0273230021002543″ url_new_window=”on” button_text=”Download a copy of the article ” button_alignment=”left” admin_label=”Call To Action Purple” _builder_version=”4.9.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#412E68″ button_border_width=”0px” button_border_radius=”40px” button_letter_spacing=”1px” button_font=”|700||on|||||” button_use_icon=”off” custom_margin=”||80px||false|false” custom_margin_tablet=”|||10%|false|false” custom_margin_phone=”|||7%|false|false” custom_margin_last_edited=”off|phone” custom_padding=”10px|30px|9px|30px|false|true” hover_enabled=”0″ button_text_size_tablet=”17px” button_text_size_phone=”16px” button_text_size_last_edited=”on|phone” sticky_enabled=”0″][\/et_pb_button][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” header_2_font=”|700|||||||” header_2_text_align=”left” header_2_text_color=”#412E68″ header_2_line_height=”1.2em” custom_padding=”||13px|||” header_2_font_size_tablet=”24px” header_2_font_size_phone=”22px” header_2_font_size_last_edited=”on|phone”]<\/p>\n

EGME<\/h2>\n

[\/et_pb_text][et_pb_text admin_label=”Text” _builder_version=”4.9.4″ _module_preset=”default” text_line_height=”1.9em” module_alignment=”center” custom_padding=”||40px||false|false”]As you could read in our newsflash from March, EGME has not been proposed by the Commission to be included in annexe XIV of REACH, which would have triggered authorisation. The REACH Committee endorsed this vote, and there were also no objections from the Parliament or the Council.<\/p>\n

Following Council decisions, EGME is one of the 12 substances moved from the Chemical Agent Directive (CAD) in order to include reprotoxic substances in the Carcinogenic & Mutagenic Directive (CMD). It can be expected that the existing iOELv will be transferred in Annex 3 of the (now) Carcinogenic & Mutagenic & Reprotoxins Directive (CMRD) as binding OEL. [\/et_pb_text][et_pb_button button_url=”https:\/\/www.esig.org\/wp-content\/uploads\/2022\/06\/202203_Newsflash_EGME.pdf” url_new_window=”on” button_text=”EGME Newsflash” button_alignment=”left” admin_label=”Call To Action Purple” _builder_version=”4.9.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#412E68″ button_border_width=”0px” button_border_radius=”40px” button_letter_spacing=”1px” button_font=”|700||on|||||” button_use_icon=”off” custom_margin=”||100px||false|false” custom_margin_tablet=”|||10%|false|false” custom_margin_phone=”|||7%|false|false” custom_margin_last_edited=”off|phone” custom_padding=”10px|30px|9px|30px|false|true” button_text_size_tablet=”17px” button_text_size_phone=”16px” button_text_size_last_edited=”on|phone”][\/et_pb_button][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” header_2_font=”|700|||||||” header_2_text_align=”left” header_2_text_color=”#412E68″ header_2_line_height=”1.2em” custom_padding=”||13px|||” header_2_font_size_tablet=”24px” header_2_font_size_phone=”22px” header_2_font_size_last_edited=”on|phone”]<\/p>\n

EGBE <\/h2>\n

[\/et_pb_text][et_pb_text admin_label=”Text” _builder_version=”4.9.4″ _module_preset=”default” text_line_height=”1.9em” module_alignment=”center” custom_padding=”||40px||false|false” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n

The 18th<\/sup> ATP (Commission Delegated regulation (EU) 2022\/692<\/a>)\u00a0to the CLP was adopted on 16<\/span>th<\/span> February 2022 and published on 3<\/span>rd<\/span> May 2022 to implement the change. The regulation\u00a0 includes EGBE classified in the Acute Toxicity Category 3 (inhalation; H331) and will apply from 1<\/span>st<\/span> December 2023.<\/span>\u00a0<\/span><\/p>\n

Manufacturers strongly disagreed with the proposed classification, and OSPA submitted detailed arguments to this effect to the two RAC and CARACAL meetings where the topic was discussed. Unfortunately, these were not accepted.\u00a0<\/span>\u00a0<\/span><\/p>\n

On the other impacts of this classification, for instance, on <\/span>SEVESO-III requirements<\/span><\/b>, we have published a FAQ document on the ESIG website – \u2018Frequently Answered Questions\u2019 sheet providing detailed answers and facts to customers of EGBE on the classification of EGBE as Acute Toxicity Category 3 (inhalation; H331).\u00a0<\/span><\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.glycol-ethers.eu\/wp-content\/uploads\/2019\/05\/FAQ-EGBE-classification_final.pdf” url_new_window=”on” button_text=”EGBE FAQs” button_alignment=”left” admin_label=”Call To Action Purple” _builder_version=”4.9.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#412E68″ button_border_width=”0px” button_border_radius=”40px” button_letter_spacing=”1px” button_font=”|700||on|||||” button_use_icon=”off” custom_margin=”||100px||false|false” custom_margin_tablet=”|||10%|false|false” custom_margin_phone=”|||7%|false|false” custom_margin_last_edited=”off|phone” custom_padding=”10px|30px|9px|30px|false|true” hover_enabled=”0″ button_text_size_tablet=”17px” button_text_size_phone=”16px” button_text_size_last_edited=”on|phone” sticky_enabled=”0″][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ disabled_on=”on|on|off” _builder_version=”4.9.4″ _module_preset=”default” background_enable_color=”off” use_background_color_gradient=”on” background_color_gradient_start=”rgba(65,46,104,0.7)” background_color_gradient_end=”rgba(65,46,104,0.7)” background_color_gradient_overlays_image=”on” background_image=”https:\/\/www.esig.org\/newsletters\/wp-content\/uploads\/2022\/06\/solvents.webp” z_index=”1″ custom_padding=”||||false|false” background_last_edited=”on|tablet” use_background_color_gradient_tablet=”off” background_enable_image_tablet=”off”][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

E-series publicationsThe glycol ethers group contributed to a publication by Jeff Kelsey on available literature and data on endocrine disrupting properties of the E-series glycol ethers (EGE). The article called \u201cEthylene oxide derived glycol ethers: A review of the alkyl glycol ethers potential to cause endocrine disruption\u201d was published in March in \u201cRegulatory Toxicology and […]<\/p>\n","protected":false},"author":1,"featured_media":1494,"parent":2026,"menu_order":7,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"folder":[37],"class_list":["post-2150","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/pages\/2150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/comments?post=2150"}],"version-history":[{"count":15,"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/pages\/2150\/revisions"}],"predecessor-version":[{"id":2319,"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/pages\/2150\/revisions\/2319"}],"up":[{"embeddable":true,"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/pages\/2026"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/media\/1494"}],"wp:attachment":[{"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/media?parent=2150"}],"wp:term":[{"taxonomy":"folder","embeddable":true,"href":"https:\/\/www.esig.org\/newsletters\/wp-json\/wp\/v2\/folder?post=2150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}